Vicapsys Life Sciences, Inc.
VICP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.84 | -3.40 | -0.06 | 0.54 |
| FCF Yield | -0.20% | -1.76% | -3.12% | -5.03% |
| EV / EBITDA | -67.37 | -23.64 | -8.00 | -28.18 |
| Quality | ||||
| ROIC | 35.32% | 66.48% | 109.38% | 276.92% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.12 | 0.35 | 0.24 | 1.87 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 70.86% | -75.28% | 46.35% | -68.88% |
| Safety | ||||
| Net Debt / EBITDA | -0.63 | -0.34 | 0.01 | 0.71 |
| Interest Coverage | -9.08 | -7.75 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -7,412.49 | -5,683.04 |